BioVie Reports Success in Early Parkinson's Disease Clinical Trial
Carson City, Friday, 7 August 2026.
BioVie’s Phase 2 trial of bezisterim successfully met its goals, demonstrating significant improvements in both motor and non-motor Parkinson’s symptoms while shifting 283 disease-related proteins toward disease-slowing patterns.
BioVie Announces Phase 2 SUNRISE-PD Results
BioVie Inc. (NASDAQ: BIVI) announced topline results from the Phase 2 SUNRISE-PD trial on 6 August 2026 [1]. The study evaluated bezisterim in patients with early-stage Parkinson’s disease who had not previously been treated with carbidopa/levodopa [2]. This multicenter, randomized, double-blind, placebo-controlled study aimed to assess the drug’s impact on neuroinflammation and insulin resistance [4]. The announcement marks a significant milestone for the clinical-stage biopharmaceutical company [3].
Clinical Endpoints and Biomarker Analysis
The trial enrolled 57 early-stage Parkinson’s disease patients randomized to receive either 20 mg of bezisterim or placebo twice daily for 12 weeks [2]. Bezisterim treatment demonstrated statistically significant improvements versus placebo on MDS-UPDRS Parts I, II, and III [1]. Additionally, 283 of 380 proteins shifted toward patterns suggesting disease slowing [4]. In terms of safety, 39.3% of the treatment group experienced adverse events versus 51.7% in the placebo group, a difference of 12.4 percentage points [4].
Strategic Webinar and Future Development
BioVie scheduled a conference call for 12 August 2026 at 4:15 p.m. ET to discuss the trial results [3]. CEO Cuong Do is scheduled to review clinical findings and the Phase 3 registrational strategy for bezisterim during the upcoming webinar [1]. The company intends to use these exploratory findings to inform the design of a future Phase 3 registrational study [4]. This event will be hosted by RedChip Companies, an investor relations firm [3].
Pipeline Context and Market Reaction
BioVie’s broader pipeline updates include the ADDRESS-LC Phase 2 trial for Long COVID and the advancement of BIV201 for complications of advanced liver disease [3]. Social media commentary noted the trial met respecified endpoints, though some market observers reacted cautiously to the readout [5]. The company emphasizes that bezisterim targets underlying disease biology rather than solely focusing on symptomatic treatment [1]. Investors await further details on the Phase 3 progression plans during the August 12 event [3].